Tirzepatide explained: the facts behind the wiki searches

How tirzepatide's dual mechanism sets it apart from other weight-loss medicines

Most GLP-1 receptor agonists work through a single pathway. Tirzepatide works through two. It binds to receptors for both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones released from the gut after eating. The combined effect slows gastric emptying, reduces hunger signals reaching the brain, and helps regulate blood sugar. The practical result is that people tend to feel full sooner and stay that way longer.

A question our prescribers hear most weeks is whether this dual action is meaningfully different from a standard GLP-1 alone, or just a marketing distinction. The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, found that tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks in adults with obesity who did not have diabetes. That is direct clinical evidence, not a theoretical one.

Tirzepatide is also the only medicine in its class with this dual mechanism currently licensed for weight management in the UK. It is a Black Triangle medicine, meaning the MHRA requires additional monitoring and reporting of side effects while its long-term profile continues to build. You can read the NHS overview of tirzepatide for a plain-English summary of how it works and what to expect.

What the trial data says, and the honest limits of what it can tell you

Numbers from clinical trials are averages, and averages hide a wide range of individual responses. With that caveat stated clearly, the SURMOUNT-1 data is striking: at the 15 mg maintenance dose, participants lost around 20–21% of their body weight on average over 72 weeks. For context, that is roughly 22 kg for someone starting at 110 kg. Those figures come from a controlled trial involving 2,539 adults, so they are not anecdote.

What the data cannot tell you is how your own body will respond, because individual factors (starting weight, metabolic health, adherence to the lifestyle changes that accompany treatment) all shift the picture. Trial participants followed structured diet and activity programmes alongside the medicine; that matters. Our tirzepatide information page covers the evidence in more depth, including what NICE concluded when it assessed the data.

The dosing schedule also shapes outcomes. The 2.5 mg starting dose exists to let your body adjust, not to produce weight loss; it typically takes several months of titration before reaching a therapeutic maintenance dose. How quickly someone moves up, and how high, is a clinical decision made with the prescriber based on tolerability and response. If you want to understand how the later stages of treatment work, our page on tirzepatide 30 explains what reaching the higher end of the dose range involves.

Who the UK licence covers, and the NHS versus private route

The UK licence covers adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present, such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. BMI alone does not guarantee a prescription; the prescriber assesses the whole picture, including medical history and current medicines. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

On the NHS, access is being phased in under NICE TA1026. The first cohort, eligible from June 2025, covers adults with a BMI of 40 or above and four or more qualifying comorbidities. A broader cohort covering BMI 35 to 39.9 became available from June 2026. NHS eligibility criteria are strict by design, and waiting times vary significantly by area.

Private treatment through a regulated online pharmacy is the alternative for people who meet the clinical criteria but fall outside the NHS thresholds or do not want to wait. If you are trying to work out where you sit, our weight-loss treatment overview explains both routes plainly. You can also explore Mounjaro specifically or compare options at this comparison page if you are deciding between branded and generic labelling.

Side effects, safety and what needs clinical oversight

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion and burping. These tend to be most noticeable after starting the medicine or after a dose increase, and for many people they settle within a week or two. Fatigue, headache and injection-site reactions are also reported. None of this is reason to avoid treatment if you are clinically suitable, but it is worth knowing before you start.

More serious events are uncommon but warrant attention. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines: if you develop severe, persistent stomach pain that radiates to the back, seek medical help promptly. Tirzepatide is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. It is not licensed for anyone under 18.

Interactions matter too. Women taking oral contraceptive pills should add a non-oral method for the first four weeks of tirzepatide treatment and for four weeks after any dose increase, because the medicine can reduce pill absorption. If you are also on HRT, NHS guidance recommends discussing transdermal options with your doctor. Details like these are exactly why clinical oversight is not a formality, and if you want to read about how treatment is structured from the beginning, our tirzepatide l page covers what the earlier stages of the programme look like. The NICE appraisal of tirzepatide (TA1026) sets out the full evidence base and the criteria under which it is recommended for use.

For a fuller view of cost context before making any decisions, our Mounjaro price comparison page explains what private treatment typically involves and what to look for in a legitimate provider. When you are ready to see whether you are clinically eligible, check your eligibility with our prescribers through a free consultation.